Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - neisseria meningitidis group b neisseria heparin binding antigen fusion protein, quantity: 50 microgram; neisseria meningitidis serogroup b outer membrane vesicles, quantity: 25 microgram; neisseria meningitidis group b factor h binding protein fusion protein, quantity: 50 microgram; neisseria meningitidis group b neisseria adhesin a protein, quantity: 50 microgram - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; histidine; sodium chloride; sucrose - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. for information on protection against specific group b strains see section 5.1 pharmacodynamic properties. bexsero is indicated for vaccination of individuals from 2 months of age and older.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - neisseria meningitidis group b factor h binding protein fusion protein, quantity: 50 microgram; neisseria meningitidis group b neisseria adhesin a protein, quantity: 50 microgram; neisseria meningitidis serogroup b outer membrane vesicles, quantity: 25 microgram; neisseria meningitidis group b neisseria heparin binding antigen fusion protein, quantity: 50 microgram - injection, suspension - excipient ingredients: sucrose; histidine; water for injections; aluminium hydroxide hydrate; sodium chloride - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. for information on protection against specific group b strains see section 5.1 pharmacodynamic properties. bexsero is indicated for vaccination of individuals from 2 months of age and older.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - neisseria meningitidis group b factor h binding protein fusion protein 50ug; neisseria meningitidis group b neisseria adhesin a protein 50ug; neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug; neisseria meningitidis sergroup b outer membrane vesicles 25ug;   - suspension for injection - 0.5 ml - active: neisseria meningitidis group b factor h binding protein fusion protein 50ug neisseria meningitidis group b neisseria adhesin a protein 50ug neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug neisseria meningitidis sergroup b outer membrane vesicles 25ug   excipient: aluminium hydroxide histidine sodium chloride sucrose water for injection - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. see section 5.1 of the data sheet for information on protection against specific group b strains bexsero is indicated for vaccination of individuals from 2 months of age and older. the use of bexsero should be in accordance with official recommendations.

Israel - Tiếng Anh - Ministry of Health

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - suspension for injection - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine - bexsero is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by neisseria meningitidis group b.

Singapore - Tiếng Anh - HSA (Health Sciences Authority)

pfizer private limited - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein - injection, suspension - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein 0.06 mg/0.5ml; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein 0.06 mg/0.5ml

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxysmal - immunosuppressants - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Canada - Tiếng Anh - Health Canada

alexion pharma gmbh - ravulizumab - solution - 10mg - ravulizumab 10mg - immunosuppressive agents

Canada - Tiếng Anh - Health Canada

alexion pharma gmbh - ravulizumab - solution - 300mg - ravulizumab 300mg

Canada - Tiếng Anh - Health Canada

alexion pharma gmbh - ravulizumab - solution - 1100mg - ravulizumab 1100mg